Kristian Villumsen - Coloplast A/S Executive VP of Chronic Care
| CLPBF Stock | USD 128.57 7.42 6.12% |
EVP
Mr. Kristian Villumsen was appointed Chief Executive Officer and Member of the Executive Management at Coloplast AS effective as of December 4, 2018. He no longer serves as Executive Vice President, Chronic Care and Member of the Executive Management of Coloplast AS, effective as of December 4, 2018. He has held the position since July 1, 2014. He no longer serves as Senior Vice President, Emerging Markets within the Company, effective as of July 1, 2014. He previously was SVP, Region Europe and SVP, Global Marketing at the Company. He was employed at the Company since 2008. He is Board Member of Chr. Hansen Holding AS. He graduated from Harvard University Kennedy School of Government in 1998 with Master of Arts degree in Public Policy. He also holds Master of Arts degree in Political Science from Aarhus Universitet from 1996 and is Lieutenant of the reserve from Danish Army Specialist Training School from 1992. since 2018.
| Age | 53 |
| Tenure | 6 years |
| Phone | 45 49 11 11 11 |
| Web | https://www.coloplast.com |
Coloplast A/S Management Efficiency
The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast A/S's management efficiency ratios could be used to measure how well Coloplast A/S manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | EVP Age | ||
| Allan Rasmussen | Coloplast A | 56 | |
| Kenji Tachibana | Sysmex Corp | 66 | |
Management Performance
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 |
Coloplast A/S Leadership Team
Elected by the shareholders, the Coloplast A/S's board of directors comprises two types of representatives: Coloplast A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coloplast. The board's role is to monitor Coloplast A/S's management team and ensure that shareholders' interests are well served. Coloplast A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coloplast A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Bjurgert, VP Relations | ||
| Allan Rasmussen, Executive VP of Global Operations | ||
| Alain Morvan, Senior Vice President Sales Europe | ||
| Thomas Barfod, Director, Employee Representative | ||
| Nicolai Andersen, Senior Vice President Wound Care | ||
| Anders LonningSkovgaard, CFO, Executive Vice President Member of the Executive Management | ||
| Kristian Villumsen, Executive VP of Chronic Care | ||
| Paul Marcun, Senior Vice President Emerging Markets | ||
| Dorthe Ronnau, VP Culture | ||
| Dennis Kaysen, Director Communications |
Coloplast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Coloplast A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 28.84 B | |||
| Shares Outstanding | 194.31 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 25.53 % | |||
| Price To Earning | 37.47 X | |||
| Price To Book | 22.60 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Coloplast Pink Sheet
Coloplast A/S financial ratios help investors to determine whether Coloplast Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast A/S security.